Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Two-year extension builds on productive relationship established in 2019
Covered in this story
What has happened since
- Gilead Sciences is up 8.2% since this was published, 15 days ago.
- Nurix Therapeutics Inc is up 14.1% since this was published, 15 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $GILD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Gilead Sciences →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.